Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Leases (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Operating Leases data on record, last reported at $40.3 million in Q4 2025.

  • For Q4 2025, Operating Leases rose 43.77% year-over-year to $40.3 million; the TTM value through Dec 2025 reached $40.3 million, up 43.77%, while the annual FY2025 figure was $40.3 million, 43.77% up from the prior year.
  • Operating Leases reached $40.3 million in Q4 2025 per FHTX's latest filing, up from $15.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $62.3 million in Q1 2021 and bottomed at $15.8 million in Q3 2025.
  • Average Operating Leases over 5 years is $40.0 million, with a median of $40.3 million recorded in 2023.
  • The widest YoY moves for Operating Leases: up 43.77% in 2025, down 47.94% in 2025.
  • A 5-year view of Operating Leases shows it stood at $51.3 million in 2021, then fell by 11.3% to $45.5 million in 2022, then decreased by 19.72% to $36.6 million in 2023, then dropped by 23.23% to $28.1 million in 2024, then soared by 43.77% to $40.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $40.3 million in Q4 2025, $15.8 million in Q3 2025, and $17.5 million in Q2 2025.